When gut spasm has 'em

Even if your patients persist with the diet you recommend, it may not be enough to control the pain and spasm of irritable bowel syndrome.

If that is the case, it's a good case for new Merbentyl 20.

A 28-day t.d.s. course of this new presentation of an established anti-spasmodic should resolve the problem.

So when diet alone just won't do, remember to get it right by writing Merbentyl 20.

Three times daily and the right diet

NEW

MERBENTYL

20 mg Dicyclomine Hydrochloride BP antispasmodic

PRESCRIBING INFORMATION

PRESENTATION: White, biconvex, oval tablets, stamped Merbentyl 20 containing Dicyclomine Hydrochloride BP 20 mg.

USES: Merbentyl is a smooth muscle antispasmodic primarily indicated for the treatment of functional conditions involving smooth muscle spasm of the gastro-intestinal tract.

DOSAGE & ADMINISTRATION: Adults and children over 12 years: One tablet (20 mg) three times daily before or after meals.

CONTRA-INDICATIONS, WARNINGS, ETC: Known idiosyncrasy to Dicyclomine Hydrochloride BP.

PRECAUTIONS: Products containing dicyclomine hydrochloride should be used with caution in any patient with or suspected of having glaucoma or prostatic hypertrophy. Use with care in patients with hiatus hernia associated with reflux oesophagitis because anticholinergic drugs may aggravate the condition. Since the risk of teratogenicity cannot be excluded with absolute certainty for any product, the drug should be used during pregnancy only if clearly needed.

It is not known whether dicyclomine is secreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dicyclomine is administered to a nursing woman.

SIDE-EFFECTS: Side-effects seldom occur with Merbentyl. However, in susceptible individuals, dry mouth, thirst and dizziness may occur. On rare occasions, fatigue, sedation, blurred vision, rash, constipation, anorexia, nausea and vomiting, headache and dysuria have also been reported.

PHARMACEUTICAL PRECAUTIONS: None. **LEGAL CATEGORY:** POM **PACKAGE QUANTITIES:** Packs of 84 tablets. **FURTHER INFORMATION:** Nil. **PRODUCT LICENCE NUMBERS:** PL 4425/0081, PA 41/5/1. **BASIC NHS PRICE:** 84 tablets £4.89 (Oct. 1986). **NAME AND ADDRESS OF LICENCE HOLDER:** Merrell Dow Pharmaceuticals Limited, Stana Place, Fairfield Avenue, Staines, Middlesex TW18 4SX. **TRADEMARKS:** Merrell, Dow, Merbentyl.

Merrell* Dow

THOMAS MORSON PHARMACEUTICALS

BUILDING FOR THE FUTURE





Building on strength
On the strength of our parent company, Merck Sharp & Dohme Limited, one of the largest manufacturers of prescribed medicines in the world.

Building on experience
On the foundations of the extensive history of Thomas Morson Pharmaceuticals, which spans over a century.

Building on research and commitment
On the benefits of sharing over £250 million invested annually by MSD on research, which has helped establish Thomas Morson Pharmaceuticals in a wide range of therapeutic areas, including arthritis and cardiovascular disease.

Building for the future
A future committed to improved patient care through medical advances in all therapeutic areas, notably gastroenterology, and the beneficial implications for the many thousands of sufferers of distressing digestive disorders.

Thomas Morson Pharmaceuticals–
new directions, new purposes

Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited

187 GEN 86 GB 1907 J

Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT . . .
- **rely on acid reduction alone**
- **rely on pepsin reduction alone**
- **rely on mucosal protection alone**
- **profoundly affect intragastric pH**

Gastrozepin DOES . . .
- **relieve daytime pain**
- **relieve night-time pain**
- **reduce antacid intake**
- **heal peptic ulcers with one 50 mg tablet b.d.**

For the treatment of peptic ulcer

Twice daily

GASTRO SELECTIVE

Gastrozepin®

pirenzepine

The gastro-selective anti-secretory

Prescribing Information; Presentation: White tablets each containing 50 mg of pirenzepine dihydrochloride scored on one face with "G" on one side of the score, and "50" on the other. The obverse is impressed with the symbol. **Uses:** Gastrozepin is indicated in the treatment of gastric and duodenal ulcers. **Dosage:** 50 mg at bedtime and in the morning before meals. In severe cases the total daily dose may be increased to 150 mg in divided doses. Continuous therapy may be recommended for up to three months. **Contra-indications, Warnings etc:** Interaction with sympathomimetics and monoamine oxidase inhibitors and Gastrozepin is a theoretical possibility. Gastrozepin is not recommended during pregnancy although in animal experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. *Side effects* occasionally transitory dry mouth and accommodation difficulty may occur. Treatment of overdosage entirely symptomatic. There is no specific antidote. **Basic NHS price:** 50 mg tablets, 60 £20.50. **Product Licence No.:** 50 mg tablets, PL0014/0260.

Further information is available on request
The Boots Company PLC Nottingham

Gastrozepin® Trade Mark

NEW PRESENTATIONS NOW AVAILABLE:
3 x 2ml ampoule pack.
10 x 1ml ampoule pack

EASY EXAMINATIONS WITH NUBAIN* ANALGESIA



- ☐ strong, effective non-MDA analgesic, suitable for use during endoscopy or colonoscopy and radiological and gynaecological investigations
- ☐ "ceiling" effect to respiratory depression reduces risks associated with opioid use[1]
- ☐ minimal effect on cardiac haemodynamics when used during catheterization[2]
- ☐ allows more accurate diagnosis of bile duct and gut obstructions due to limited interference with function[3] and motility[4]

NUBAIN*
nalbuphine hydrochloride

Effective, comfortable analgesia during clinical investigations

Prescribing Information

Presentation: Nubain* Injection, 20mg of nalbuphine hydrochloride in 2ml ampoules or 10mg nalbuphine hydrochloride in 1ml.

Uses: For the relief of moderate to severe pain including pain associated with myocardial infarction. Can be used as a premedication and as a component of balanced anaesthesia.

Dosage and Administration: 10-20mg for a 70kg individual, adjusted according to the severity of pain, physical status of the patient and concomitant medications. Suspected myocardial infarction usual dose 20mg by slow i.v. injection. Some patients may be successfully managed on 10mg while others may need to have the dose increased to 30mg. In absence of pain relief a repeat dose may be given within 30 minutes. Nubain may be administered by patient controlled on-demand i.v. infusion. Nubain is not recommended for children.

Contra-Indications: Hypersensitivity to Nubain.

Precautions and Warnings: Use with care in known and potential opioid abusers. Also care in active patients who may drive or operate machinery. Caution in patients with impaired respiration. Caution and dose reduction in patients with impaired renal or hepatic function. Safe use not established in pregnancy and in conditions of raised intracranial pressure. Abrupt discontinuation of chronic therapy may produce withdrawal symptoms.

Side Effects: The most frequent reaction is sedation. Also sweating, nausea, vomiting, dizziness, dry mouth, vertigo and headache and other opioid effects may occur.

Product Licence No.: PL 4524/0003.

NHS Price: £11.60 per box of 10 x 2ml ampoules. £3.69 per box of 3 x 2ml. £7.50 per box of 10 x 1ml ampoules.

References: 1. Julien RM. Effects of nalbuphine on normal and oxymorphone-depressed ventilatory responses to carbon dioxide challenge. Anaesthesiology 1982;57:No 3A.
2. Fahmy NR, Sunder N, Soter NA. A comparison of histamine releasing properties and hemodynamic effects of morphine and nalbuphine in humans. Anesth Analg 1984;63:175.
3. Vatashsky E, Haskel Y. The effect of nalbuphine (Nubain®) compared to morphine and fentanyl on common bile duct pressure. Curr Ther Res 1985;37,1:95-102.
4. Shah M, Rosen M, Vickers MD. Effect of premedication and diazepam, morphine or nalbuphine on gastrointestinal motility after surgery. Br J. Anaesth 1984;56:1235-8.

Further information is available on request from Du Pont (UK) Limited, Pharmaceuticals, Wedgwood Way, Stevenage, Hertfordshire SG1 4QN. Telephone: (0438) 734549.

Du Pont Pharmaceuticals DUPONT



A new trial[1] has shown that COLIFOAM is equal in efficacy to prednisolone enemas, but causes significantly less interference in your patients' daily lives. Published evidence now conclusively demonstrates the clear superiority of COLIFOAM compared to liquid enemas:

Efficacy. COLIFOAM is equal in efficacy to prednisolone enemas[1] and hydrocortisone enemas[2]. Retrograde spread increases with the extent of the disease[3] and COLIFOAM can reach well into the descending colon[4].

Acceptability. COLIFOAM causes less interference with your patients' daily lives[1,2,5]. COLIFOAM is far easier for your patients to retain[1,2,5].

Safety. Bioavailability data proves COLIFOAM has extremely low levels of systemic absorption[6], lower than prednisolone enemas[7].

Economy. COLIFOAM costs less per dose than standard proprietary enemas[8].

In distal inflammatory bowel disease. A better choice every time.

References (1) Somerville KW et al. British Medical Journal 1985;291:866. (2) Ruddell WSJ et al. Gut 1980;21:885-889. (3) Farthing MGJ et al. British Medical Journal 1979;2:822-824. (4) Rhodes JM. Journal of Clinical & Hospital Pharmacy 1983;8:219-232. (5) Gaucher P and Champignuelle B. Revue Française de Gastroenterologie 1983;193:35-39. (6) Barr WH et al. Medical College of Virginia/Virginia Commonwealth University. FDA bioavailability submission document. October 1981. (7) Lee DAH et al. Gut 1980;21:215-218. (8) MIMS October 1985.

Prescribing Information. Presentation White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. Uses Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use, (illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. Contra-indications, warnings etc. Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Shake vigorously before use. Keep out of reach of children. For external use only. Legal category POM. Package quantities Aerosol canister containing 25g. (approx. 14 applications) plus a plastic applicator and illustrated leaflet. Basic NHS cost 25g plus applicator, £7.25. Further Information One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No. 0036/0021. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Hatfield, Herts. AL10 0NZ.

The Focus of Medical Technology.

As the medical profession searches tirelessly for the means to further the investigation and treatment of conditions which have so far eluded it, there is one company motivated towards helping achieve that end.

The company is Pilkington Medical Systems. Their expertise in electro-optical systems as manufacturers of **medical lasers** and **endoscopes** combined with the considerable **research** and **development** capability has positioned them as one of the world's foremost medically innovative companies.

So, as the world looks for the next healthcare breakthrough, the medical profession can look to Pilkington Medical Systems – the focus of medical technology.

PILKINGTON

◄ Medical Systems ►

The Focus of Medical Technology.

Pilkington Medical Systems Ltd. Bleasdale Court, 2 South Avenue, Clydebank Business Park, Clydebank G81 2LE. Telephone: 041-952 1111 · Telex: 776471

ASACOL™

MESALAZINE*(5-aminosalicylic acid)

Direct delivery to the colon

For ulcerative colitis patients who cannot tolerate sulphasalazine[1]



ASACOL delivers 5-aminosalicylic acid directly to the colon without sulphapyridine (the agent in sulphasalazine that can cause distressing side effects).[2]

A patented acrylic coating on **ASACOL** makes it site-selective. **ASACOL** remains intact until it reaches the colon, where pH rises above 7 and dissolves the coating, releasing the 5-ASA.[2,3]

Each **ASACOL** tablet provides twice as much 5-ASA (400mg) as each tablet of sulphasalazine (200mg), which allows patients to take fewer tablets daily.

Clinical studies have shown that **ASACOL** offers efficacy comparable to that of sulphasalazine in maintaining the remission of ulcerative colitis.[4,5]

ASACOL™

Direct Delivery to the Colon

REFERENCES:

1 Dew M J Harries A D Evans B K et al Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine *Lancet* 1983 ii 801

2 Dew M J Hughes P J Lee M G et al An oral preparation to release drugs in the human colon *Br J Clin Pharmacol* 1982 14 405-408

3 Dew M J Ryder R E J Evans N et al Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis *Br J Clin Pharmacol* 1983 16 185-187

4 Dew M J Hughes P J Harries A D et al Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid *Br Med J* 1982 285 1012-1014

5 Dew M J Harries A D Evans N et al Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth *Br Med J* 1983 287 23-24

***Mesalazine is the British Approved Name for 5-aminosalicylic acid.**

ABBREVIATED PRESCRIBING INFORMATION

PRESENTATION

Red tablets containing 400mg of mesalazine (5-aminosalicylic acid) coated for release in the terminal ileum and colon

USES

For the maintenance of remission of ulcerative colitis in patients who cannot tolerate sulphasalazine

DOSAGE AND ADMINISTRATION

Adults: 3 to 6 tablets daily in divided doses.
There is no dose recommendation for children

CONTRA-INDICATIONS, WARNINGS, ETC.

Contra-indications

Contra-indications: a history of sensitivity to salicylates
Children under 2 years of age

Precautions

Renal disorder: Mesalazine is excreted rapidly by the kidney mainly as its metabolite, N-acetyl 5-aminosalicylic acid. In rats large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Although no renal toxicity has been reported in patients taking Asacol, it is not recommended in patients with renal impairment and caution should be exercised in patients with a raised blood urea or proteinuria.

Asacol should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine.

Adverse Reactions

Adverse reactions occur in a small proportion of patients who previously could not tolerate sulphasalazine. The side-effects are predominantly gastrointestinal (nausea, diarrhoea and abdominal pain) and headache. Asacol may be associated with the exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine.

Other side effects observed with sulphasalazine such as depression of bone marrow and of sperm count and function have not been reported with Asacol.

LEGAL CATEGORY: POM

PL: 0424/0032

Daily treatment cost: 87 pence

U.K. Patent No. 8322387

Henlow Trading Estate
Henlow, Beds. SG16 6DS

SALAZOPYRIN® EN
sulphasalazine

HAS TOLERABILITY ALL WRAPPED UP

"Patients in whom sulfasalazine induces dyspeptic symptoms alone can be given EN Salazopyrin (entero-soluble) instead, and no more than 5% of these patients will be so troubled by dyspepsia that the treatment has to be discontinued."
Nielsen, O.H., Scand. J. Gastroenterol., 1982, 17, 389



Get them into the habit

DAY AFTER DAY AFTER YEAR

500mg q.i.d. in ulcerative colitis

PRESCRIBING INFORMATION

Dosage and Administration Plain or EN Tabs: In acute moderate attacks 2-4 tablets 4 times a day. In severe attacks give steroids also. Gradually reduce dose after 2-3 weeks to 3-4 tabs/day given indefinitely. Suppositories: Two morning and night reducing dose after 3 weeks with improvement. Enema: One to be given at bedtime. Preparation contains adult dose. Children: Reduce adult dose on basis of bodyweight.

Contra-indications Sensitivity to salicylates and sulphonamides. Infants under 2 years. Enema: Sensitivity to parabens.

Adverse Reactions Side effects common to salicylates or sulphonamides may occur. Most commonly these are nausea, loss of appetite and raised temperature which may be relieved on reduction of dose, use of EN tablets, enema or suppositories. If serious reactions occur the drug should be discontinued. Rare Adverse Reactions: Haematological: haemolytic anaemia, agranulocytosis, aplastic anaemia. Hypersensitivity: eg rash, fever. Gastrointestinal: eg stomatitis, impaired folate uptake. C.N.S.: eg peripheral neuropathy. Fertility: eg reversible oligospermia. Renal: eg proteinuria, crystalluria. Also: Stevens-Johnson syndrome and lung complications: eg fibrosing alveolitis.

Precautions Care in porphyria, allergic, renal or hepatic disease. Glucose 6-PD deficiency. Blood checks initially and periodically.

Pregnancy and Lactation While the ingestion of drugs in these situations may be undesirable, the severe exacerbations of the disease which can occur commends the continuance of therapy. Long clinical usage and experimental studies have failed to reveal teratogenic or icteric hazards. The amounts of drug present in the milk should not present a risk to a healthy infant.

Packages and Prices Plain Tablets (0·5g) 100 & 500: £6·70 for 100. EN Tablets (0·5g) 100 & 500: £8·70 for 100. Suppositories (0·5g) 10 & 50: £2·80 for 10. Enemas (3·0g) 7: £12·10 for 7.
Product Licence Numbers Plain Tablets 0009/5006. EN Tablets 0009/5007. Suppositories 0009/5008. Enema 0009/5009.

Pharmacia

Further information is available on request
Pharmacia Limited, Pharmacia House,
Midsummer Boulevard, Milton Keynes MK9 3HP
Telephone Milton Keynes (0908) 661101

Created by Nature. Proven by Science.

For relief of irritable bowel and abdominal pain



The unique enteric-coated Colpermin capsule is a long-acting, slow-release product containing a thixotropic paste of peppermint oil. The enteric coating permits this naturally occurring medication to be delivered direct to the distal small bowel. Recent studies confirm that Colpermin offers direct relief to the patient by effectively relaxing intestinal smooth muscle to relieve colonic pain and gaseous distension.

- Irritable bowel symptoms are highly responsive to placebo, but in a recent double-blind cross-over trial, Colpermin was found to be superior to placebo in alleviating irritable bowel symptoms over a three-week period.[1]

- A delayed-release preparation, Colpermin reaches the colon in an unmetabolised state, allowing it to effectively reduce colonic motility.[2]

- Recent ultrasound studies show a consistent inhibitory effect of topical peppermint oil on colon motility and symptomatic improvement of irritable bowel patients given peppermint oil.[3]

References:

1. Rees WDW, Evans BK, Rhodes J: Treating irritable bowel syndrome with peppermint oil. *Br Med J* 2:835-836, 1979.

2. Somerville KW, Richmond CR, Bell GD: Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: A pharmacokinetic study. Proceedings of the British Pharmacological Society, Cambridge, April 1983. *Br J Clin Pharmacol*, to be published.

3. Taylor BA, Duthie HL, Oliveira RB, et al: Ultrasound used to measure the response of colonic motility to essential oils. Proceedings of *The International Motility Symposium* Aix-en-Provence, France, September 1983, to be published.

COLPERMIN™

(enteric-coated peppermint oil) CAPSULES



PRESCRIBING INFORMATION

Presentation: Enteric-coated gelatin capsule. Each contains 0.2 ml standardised peppermint oil B.P., Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should *not* be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years.

Tillotts LABORATORIES

Contraindications, Warnings, etc. Precautions: The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424 0009. **Basic NHS Cost:** £10.58 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds.
European Patent No. 0015334. **UK Patent No. 2006011.**

Henlow Trading Estate, Henlow, Beds. SG16 6DS

Another cleaning solution from KeyMed



Manual cleaning and disinfection of fiberscopes is a tedious and time-consuming task set against a background of the increased risk of cross-infection. Automated processing ensures a regimented and pre-determined level of decontamination on a repeatable basis.

The New KeyMed Auto-Disinfector

RELIABLE processes all Olympus OES immersible fiberscopes providing the benefits of total immersion and all channel irrigation*.

VERSATILE self-contained, mobile and requires no plumbing.

SIMPLE scope connections are quick and easy and all functions are operated from a convenient eye-level control panel.

The KeyMed Auto-Disinfector has two pre-set programmes and also incorporates a pause facility to allow prolonged endoscope immersion in disinfectant solution when required.

For further information or to arrange a practical evaluation of the KeyMed Auto-Disinfector in your own unit, contact Medical Customer Liaison at any of the numbers below.

**excluding raiser bridge channel on JF series, GIF-K10 and GIF-D10.*



Eye-level control panel operates all functions

Quick and easy scope connections



Simple access to fluid containers

DESIGNED FOR ALL OLYMPUS IMMERSIBLE FIBERSCOPES

KeyMed

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, Essex SS2 5QH.
Telex: 995283, Facsimile: (0702) 65677, Telephone: (0702) 616333 (24 lines).

Scotland: KeyMed, Peel House, Ladywell East, Livingston EH54 6AH. Telephone: (0506) 416655

Ireland: KeyMed Ireland Ltd., KeyMed House, Lord Edward Court, Bride Street, Dublin 8. Telephone: 774855

USA: KeyMed Inc., 400 Airport Executive Park, Spring Valley, New York 10977. Telephone: (914) 425-3100

Medical Equipment

DE-NOL REBALANCES THE ULCER EQUATION

- Local cytoprotective action.
- As effective as the H_2 antagonists.
- Lower relapse rates than H_2 antagonists.
- Heals 85% of H_2 antagonist failures.
- Favours lower relapse rates in smokers.



The inescapable equation of ulcer aetiology Acid Attack v. Mucosal Defence remains the basis for our understanding of peptic ulcer. With an ulcer the acid side of the equation gains the upper hand, although it is now clear that this is more often a result of poor mucosal resistance than excessive acid secretion. An agent which enhances the mucosal defence mechanism should be the treatment of choice. The approach to ulcer therapy should thus be based on the truism:

NO MUCOSAL BREAKDOWN, NO ULCER.

De-Nol®

Gist-brocades Brocades/Great Britain) Limited, West Byfleet, Surrey. tri-potassium di-citrato bismuthate

Prescribing Information De-Noltab and De-Nol

Presentation: De-Noltab is presented as flat round pink tablets, each tablet containing 120mg tri-potassium di-citrato bismuthate (calculated as Bi_2O_3). De-Nol is presented as a clear red liquid in a 560ml bottle containing 120mg tri-potassium di-citrato bismuthate (calculated as Bi_2O_3) in each 5ml. **Uses:** Ulcer healing agent. For the treatment of gastric and duodenal ulcers. **Dosage and administration:** By oral administration. Each tablet is to be crushed in the mouth and swallowed with a draught of water. Each dose of the liquid presentation is to be diluted with 15ml of water. ADULTS: One tablet or 5ml dose four times a day on an empty stomach, half an hour before each of the three main meals and two hours after the last meal of the day. The treatment course should be taken for the full 28 day period and it is important that a dose is not missed. If necessary, one further course of therapy may be given. Maintenance therapy with De-Noltab/De-Nol is not indicated. CHILDREN: As for adults. **Contra-indications, Warnings, etc:** De-Noltab and De-Nol should not be administered to patients with renal disorders, and on theoretical grounds the products are contra-indicated in pregnancy. SPECIAL PRECAUTIONS: De-Noltab and De-Nol may inhibit the efficacy of orally administered tetracyclines. SIDE EFFECTS: Blackening of the stool usually occurs. Darkening of the tongue, nausea and vomiting have been reported. OVERDOSAGE: No reports of overdosage have been received; gastric lavage and, if necessary, supportive therapy would be indicated. **Pharmaceutical precautions:** Normal pharmaceutical storage and handling are indicated. **Legal category:** P. **Package quantities:** DE-NOLTAB: Foil treatment packs of 112 tablets. DE-NOL: Treatment packs of 560ml. **Basic N.H.S. Price:** De-Noltab £15.84. De-Nol £10.31. **GMS Price (Eire):** De-Noltab IR£20.99. De-Nol IR£13.66. **Further information:** Some patients with an associated gastritis may experience an initial discomfort whilst taking De-Nol liquid. Milk should not be drunk by itself during the course of treatment as this can prevent the medicine from working properly. Small quantities of milk on a breakfast cereal or in tea or coffee taken with meals are permissible. Antacids should not be taken for half an hour before or half an hour after taking a dose of De-Noltab/De- Nol as these can interfere with the action of the drug. **Product Licence Numbers:** De-Noltab: 0166/0102. De-Nol: 0166/5024. **Product Authorisation Numbers:** De-Noltab: 62/22/1. De-Nol: 62/23/1.

A SENSE OF ASHER

A further collection of the writings of Richard Asher, selected and introduced by Ruth Holland

This second selection of Richard Asher's writings, with an introduction by Ruth Holland, was originally published in a limited edition in the Keynes Press in 1983. It sold out rapidly and in response to exceptional demand it was decided to produce a paperback edition. This contains the complete text of the original and has a new cover based on one of the original designs for Lewis Carroll's *The Hunting of the Snark* by Henry Holiday.

"The contents of this volume are pure delight: arresting, provoking and full of good sense as only Richard Asher knew how to present it."

"Even his most serious and weighty articles sparkle with sequins—his own aphorisms, imaginary dialogue, fantasies, quotations—and he had that knack of being always entertaining, which Shaw described as having your pockets stuffed with sausages and keeping a red hot poker in the fire."



Price: Inland £7.00;
Overseas £8.50; USA $14.00
(BMA members:
Inland £6.50; Overseas £8.00;
USA $13.00).

Overseas prices include air mail postage.

Payment must be enclosed with order.

Order from:
The Publisher,
BRITISH MEDICAL JOURNAL,
BMA House,
Tavistock Square,
London WC1H 9JR,
or your bookseller.

THE KEYNES PRESS

Limited editions of medical classics, published under an imprint named after Sir Geoffrey Keynes

	UK	Abroad	USA
The Portraiture of William Harvey by Sir Geoffrey Keynes	£40.00	£46.00	$64.50
Instincts of the Herd in Peace and War, by William Trotter	£45.00	£52.00	$73.00
A Varied Life: Memoirs of a Swansea GP, the diaries of Urban Marks	£35.00	£37.50	$52.50
Platt versus Pickering	£45.00	£51.00	$71.50
Notes on the Composition of Scientific Papers, by Sir Clifford Allbutt	£35.00	£39.50	$55.50
The Anatomy of Courage, by Lord Moran	£35.00	£41.00	$57.50

Order from the Publishing Manager (Keynes Press), BMA House, Tavistock Square, London WC1H 9JR. All prices include registered postage, by air abroad. Please make your cheque payable to the *British Medical Journal*.

SCANDINAVIAN JOURNAL OF Gastroenterology

VOLUME 21, SUPPLEMENT 123, 1986

CONTENTS

Introductory Remarks	*G. N. J. Tytgat*	ii
Technique of Endoscopic Ultrasonography Investigation: Esophagus, Stomach and Duodenum	*G. C. Caletti, L. Bolondi, Lorena Zani & G. Labò*	1
A Fundamental Study of Normal Layer Structure of the Gastrointestinal Wall Visualized by Endoscopic Ultrasonography	*T. Aibe, T. Fuji, K. Okita & T. Takemoto*	6
Problems and Variations in the Interpretation of the Ultrasound Feature of the Normal Upper and Lower GI Tract Wall	*L. Bolondi, G. Caletti, P. Casanova, V. Villanacci, W. Grigioni & G. Labò*	16
Endoscopic Ultrasonography of Normal and Pathologic Upper Gastrointestinal Wall Structure. Comparison of Studies in Vivo and in Vitro with Histology	*T. L. Tio & G. N. J. Tytgat*	27
Ultrasound and the Intestinal Wall: Experimental Methods	*F. Silverstein, M. Kimmey, R. Martin, R. Haggitt, L. Mack, A. Moss & D. Franklin*	34
Benign Lesions of the Upper GI Tract by Means of Endoscopic Ultrasonography	*W. D. Strohm & M. Classen*	41
Malignant Lesions of the Upper Gastrointestinal Tract	*N. Heyder & G. Lux*	47
Endoscopic Ultrasonography in Detection and Staging of Gastric Non-Hodgkin Lymphoma. Comparison with Gastroscopy, Barium Meal, and Computerized Tomography Scan	*T. L. Tio, F. C. A. Den Hartog Jager & G. N. J. Tytgat*	52
Endoscopic Ultrasonography in the Diagnosis of Submucosal Tumor of the Upper Digestive Tract	*K. Yasuda, M. Nakajima & K. Kawai*	59
Sonoendoscopic Evaluation of Extraesophageal and Extragastric Abnormalities: A Review	*M. D. Rifkin & S. J. Gordon*	68
Detection of Portal Hypertension and Esophageal Varices by Means of Endoscopic Ultrasonography	*G. C. Caletti, L. Bolondi, L. Zani, E. Brocchi, G. Guizzardi & G. Labò*	74
The Role of Endoscopic Ultrasonography in Assessing Local Resectability of Oesophagogastric Malignancies. Accuracy, Pitfalls, and Predictability	*T. L. Tio, F. C. A. Den Hartog Jager & G. N. J. Tytgat*	78
Transrectal Ultrasonography: Interpretation of Normal Intestinal Wall Structure for the Preoperative Staging of Rectal Cancer	*M. Boscaini & A. Montori*	87
Endorectal Sonographic Prospective Staging of Rectal Cancer	*M. D. Rifkin, E. T. McGlynn & G. Marks*	99
Comparison of Blind Transrectal Ultrasonography with Endoscopic Transrectal Ultrasonography in Assessing Rectal and Perirectal Diseases	*T. L. Tio & G. N. J. Tytgat*	104
Endoscopic Ultrasonography of the Pancreas. Technical Aspects	*G. Lux & N. Heyder*	112
Endosonographic Diagnosis of Benign Pancreatic and Biliary Lesions	*H. Dancygier & M. Classen*	119
Endoscopic Ultrasonography of Chronic Pancreatitis and Pancreatic Pseudocysts	*W. R. Lees*	123
Endoscopic Ultrasonography in the Differential Diagnosis of Pancreatic Disease. A Preliminary Report	*M. V. Sivak, Jr. & A. Kaufman*	130
Endoscopic Ultrasonography in Staging Local Resectability of Pancreatic and Periampullary Malignancy	*T. L. Tio & G. N. J. Tytgat*	135
Technical Aspects of Endoscopic Ultrasonography of the Biliary System	*K. Yasuda, M. Nakajima & K. Kawai*	143
Endoscopic Ultrasonography of Bile Duct Malignancy and the Preoperative Assessment of Local Resectability	*T. L. Tio & G. N. J. Tytgat*	151
Endoscopic Ultrasonography in Analysing Peri-Intestinal Lymph Node Abnormality. Preliminary Results of Studies in Vitro and in Vivo	*T. L. Tio & G. N. J. Tytgat*	158

Annual subscription (ten issues per year) NOK 1,300,-/ USD 216.00

Publisher: Norwegian University Press (Universitetsforlaget/AS), P.O. Box 2959 Tøyen, Oslo 6, Norway.
U.S. address: P.O. Box 258, Irvington-on-Hudson, NY 10533, USA

ASK THE MAN WHO USES A FUJINON ENDOSCOPE

He'll tell you about Fujinon reliability – unsurpassed by any endoscope in current production. In fact Pyser have such great confidence in their Fujinon endoscopes that they offer what we believe to be the best guarantee in the world! 12 MONTHS UNCONDITIONAL GUARANTEE INCLUDING ACCIDENTAL DAMAGE. This means that the true cost of the instrument including revenue implications is precisely known from the outset. 18 MONTHS COVER FOR MATERIALS AND WORKMANSHIP which means that for a period of six months extended beyond the first twelve months any fault traceable to material or workmanship will be rectified at NO COST.

He'll tell you about the service for Fujinon endoscopes. We recommend that you pay a visit to Edenbridge Kent to see for yourself and will be happy to arrange this.

He'll tell you that should you need a loan instrument Pyser make one available to you ... no quibble.

He'll tell you about a UNIQUE Pyser Service... Endoscope Health Check ... which is operative to all Fujinon users as they take delivery. A senior Fujinon trained technician visits customers' units to carry out a full survey of the instruments. He submits a written report with recommendations. Pyser ensures that a visit is made AT LEAST ONCE EVERY THREE MONTHS. THIS SERVICE CARRIES NO CHARGE and is introduced to prevent minor problems becoming major disruptions to your endoscopy service.

He'll tell you how installation of instruments is carried out by a Pyser technician who ensures that the specification we have agreed and proposed is met in its entirety. This installation includes a full demonstration of cleaning and maintenance techniques.

Pyser, an efficient caring organisation, distributor of Fujinon high reliability endoscopes. Ask the man who uses one!

FUJINON

For further information on Fujinon endoscopes contact Felicity Findlay, Pyser Ltd., Fircroft Way, Edenbridge, Kent TN8 6HA. Tel: Edenbridge (0732) 864111.